APTO - Aptose Biosciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-1.371M

Cash

23.31M

Avg Qtr Burn

-10.11M

Short % of Float

0.55%

Insider Ownership

2.67%

Institutional Own.

27.63%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tuspetinib mono/combo w/ Venetoclax Details Acute myeloid leukemia, Cancer, Leukemia, Relapsed/refractory acute myeloid leukemia	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Luxeptinib (CG-806) (BTK and FLT3 Inhibitor) Details Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Acute myeloid leukemia, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APTO-253 (MYC inhibitor) Details Acute myeloid leukemia, Cancer, Myelodysplastic syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tuspetinib (HM43239) & luxeptinib Details Acute myeloid leukemia, B-cell malignancies, Relapsed/refractory acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.